Clincal study of umbilical cord-derived mesenchymal stem cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem cell transplantation--multicenter, randomized parallel controlled trial

Clincal study of umbilical cord-derived mesenchymal stem cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem cell transplantation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-16007806

Enrollment

Unknown

Registered

2016-01-20

Start date

2016-04-01

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HLA-haploidentical hematopoietic stem cell transplantation patients with hematologic malignancies

Interventions

MSCs group:Infusion umbilical cord-derived MSCs (1*10^6/kg, per 2 weeks, total 4 times)

Blank Control:None

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. HLA-haploidentical HSCT patients did not occured GVHD; 2. Age between 18 to 60; 3. KPS score > 60; 4. No serious organ dysfunction; 5. Expected survival > 3 months.

Exclusion criteria

Exclusion criteria: 1. Have serious organ dysfunction; 2. Combined with other cancer need treatment; 3. Presence of clinical signs of brain dysfuntion or severe mental illness can not comply with the study protocol; 4. Loss to follow-up; 5. Unable to cooperate.

Design outcomes

Primary

Measure	Time frame
Incidence of Severe Chronic graft versus host disease;	—

Secondary

Measure	Time frame
Recurrence rate;Overall survival rate;Disease free survival rate;Security;Lymphocyte subset;	—

Countries

China

Contacts

Public ContactXi Zhang

Department of Hematology, Xinqiao Hospital, Third Military Medical University

zhangxxi@sina.com+86 138 0831 0064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026